Results from the Phase 3 POETYK PSO-1 and POETYK PSO-2 trials show that response rates for deucravacitinib continued to extend through Week 24 and were maintained through Week 52 in patients with moderate to severe plaque psoriasis
Deucravacitinib demonstrated efficacy no matter baseline characteristics, including weight , disease severity and former treatment with biologic or non-biologic therapies
Patients on deucravacitinib demonstrated significantly greater improvements from baseline in psoriasis signs and symptoms compared with placebo and Otezla® (apremilast) at Week 16, with the best improvement in symptoms reported for itch and skin tightness
No clinically meaningful changes from baseline levels in laboratory parameters compared to placebo or Otezla, according to data previously presented, with findings confirming no cumulative trends
Bristol Myers Squibb (NYSE: BMY) today announced that data from 19 company-sponsored scientific presentations are being shared at the ecu Academy of Dermatology and Venereology (EADV) 30th Anniversary Congress happening Michaelmas – October 2, 2021. The research, which spans clinical, health economics and outcomes research, translational, clinical pharmacology and preclinical presentations, highlights the breadth and depth of the company’s data on deucravacitinib, a first-in-class, oral, selective tyrosine kinase 2 (TYK2) inhibitor, also because the emerging dermatology pipeline.
Clinical research being presented at the meeting includes findings from new analyses of the worldwide pivotal Phase 3 POETYK PSO-1 and POETYK PSO-2 trials in moderate to severe plaque psoriasis showing deucravacitinib demonstrated:
Durable efficacy through one year of treatment, with maximum response rates achieved by Week 24 [as measured by Psoriasis Area and Severity Index (PASI) 75, PASI 90, PASI 100, static Physician’s Global Assessment score of clear or almost clear (sPGA 0/1) and sPGA 0] and maintained through Week 52 (POETYK PSO-1). These data (Presentation #2857) are being presented today during the Late Breaking News Session from 3:45 – 4:45 p.m. CEST. Deucravacitinib also demonstrated durable efficacy in scalp psoriasis through 52 weeks of treatment (Poster Number: P1391).
Efficacy across a broad range of patient subgroups, with a consistently higher percentage of patients receiving deucravacitinib versus placebo and Otezla®(apremilast) achieving PASI 75 and sPGA 0/1 response at Week 16 no matter prior psoriasis treatment, baseline disease characteristics and baseline demographic factors. Data on the efficacy of deucravacitinib, no matter prior psoriasis treatment (Presentation FC03.06), were featured as an public speaking today from 2:30 – 3:30 p.m. CESTidentified through 52 weeks of knowledge . Laboratory data now shown from the trials for Weeks 0 to 52 (beyond what was initially presented for Weeks 0 to 16) confirmed no clinically meaningful changes from baseline levels observed in any laboratory parameters, including total cholesterol, creatine phosphokinase, neutrophils and platelets, which are four parameters that are known to vary with Janus kinase (JAK) 1, 2 and three inhibition, and confirmed no cumulative trends (Poster Number: P1407).
Deucravacitinib (pronounced doo-krav-a-sih-ti-nib) may be a first-in-class, oral, selective tyrosine kinase 2 (TYK2) inhibitor with a singular mechanism of action and is that the first and only selective TYK2 inhibitor in clinical studies across multiple immune-mediated diseases. Bristol Myers Squibb scientists designed deucravacitinib to selectively target TYK2, thereby inhibiting signaling of interleukin (IL)-23, IL-12 and sort 1 interferon (IFN), key cytokines involved within the pathogenesis of multiple immune-mediated diseases. Deucravacitinib achieves a high degree of selectivity by binding to the regulatory domain of TYK2, leading to allosteric inhibition of TYK2 and its downstream functions. Deucravacitinib selectively inhibits TYK2, unlike approved Janus kinase (JAK) 1, 2 and three inhibitors, at physiologically relevant concentrations. At therapeutic doses, deucravacitinib doesn’t inhibit JAK1, JAK2 or JAK3. thanks to the innovative design of deucravacitinib, Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for the science underpinning the clinical development of deucravacitinib.
Deucravacitinib is being studied in multiple immune-mediated diseases, including psoriasis, rheumatoid arthritis , lupus and inflammatory bowel disease. additionally to POETYK PSO-1 and POETYK PSO-2, Bristol Myers Squibb is evaluating deucravacitinib in three other Phase 3 studies in psoriasis: POETYK PSO-3 (NCT04167462); POETYK PSO-4 (NCT03924427); POETYK PSO-LTE (NCT04036435). Deucravacitinib isn’t approved to be used in any country.
Psoriasis may be a widely prevalent, chronic, systemic immune-mediated disease that substantially impairs patients’ physical health, quality of life and work productivity. Psoriasis may be a serious global problem, with a minimum of 100 million people worldwide impacted by some sort of the disease, including around 14 million people in Europe and approximately 7.5 million people within the us . Nearly one-quarter of individuals with psoriasis have cases that are considered moderate to severe. Up to 90 percent of patients with psoriasis have psoriasis vulgaris, or plaque psoriasis, which is characterized by distinct round or oval plaques typically covered by silvery-white scales. Despite the supply of effective systemic therapy, many patients with moderate to severe psoriasis remain undertreated or maybe untreated and are dissatisfied with current treatments. People with psoriasis report an impression on their emotional well-being, straining both personal and professional relationships and causing a reduced quality of life. Psoriasis is related to multiple comorbidities which will impact patients’ well-being, including rheumatoid arthritis , disorder , metabolic syndrome, obesity, diabetes, inflammatory bowel disease and depression.
About Bristol Myers Squibb
Bristol Myers Squibb may be a global biopharmaceutical company whose mission is to get , develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.
Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol-Myers Squibb Company. In certain countries outside the U.S., thanks to local laws, Celgene and Juno Therapeutics are mentioned as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company.
Otezla® (apremilast) may be a registered trademark of Amgen Inc.
Source link: https://investors.bms.com/